Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Health Technology

Oncology

IdentiClone Dx IGH Assay Certification

More Like This

Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications

AliveDx receives IVDR Certification of its Manufacturing Sites in Switzerland and United Kingdom

Invivoscribe Announces Registration of the LeukoStrat® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials

AliveDx Receives IVDR CE Mark for Groundbreaking Microarray Immunoassay in Allergy Diagnostics

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide